Dupixent Wins Approval in Europe for COPD
The European Commission has approved Dupixent as an add-on treatment for adults with uncontrolled COPD.
Category: Intl’ Pharmaceuticals
Intl' Pharmaceuticals
LatestIntl' Pharmaceuticals
LatestHealth Canada OKs Trikafta for Younger Children With Cystic Fibrosis
Health Canada granted market authorization for the expanded use of Trikafta to include children with cystic fibrosis ages 2-5 years who have at least one copy of the F508del mutation in the CFTR gene.
Intl' Pharmaceuticals
Latest
Frequent Visits to Green Spaces Linked to Less Prescription Medication Use
Frequent visits to urban green spaces, such as parks and community gardens, rather than the amount, or views of them from home, may be linked to lower use of certain prescription medications.
Switching to Dry Powder Inhaler Cuts Carbon Footprint of Asthma Medication Delivery
Researchers say the hydrofluorocarbons in pressurized metered dose inhalers are potent greenhouse gases and switching to dry powder inhalers would cut emissions while not worsening asthma management.
Read More
FDA Approves Generic Roflumilast for COPD
The FDA has approved a generic version of roflumilast manufactured by Zydus Pharmaceuticals USA Inc for the treatment of COPD.
Read More
Canada Authorizes Novavax COVID-19 Vaccine for Adults
Health Canada has granted authorization for Novavax Inc’s COVID-19 vaccine “Nuvaxovid” for adults age 18 and older.
Read More
Positive Results for Novavax Vaccine in Children
Novavax Inc’s COVID-19 vaccine demonstrated 80% efficacy overall in a study of over 2,000 pediatric patients when the Delta variant was the predominant circulating strain in the US.
Read More
Novavax Vaccine Authorized in Great Britain, New Zealand
Novavax Inc has received authorizations for its COVID-19 vaccine NVX-CoV2373 (brand name Nuvaxovid) in Great Britain and in New Zealand, the company reports.
Read More
Positive Data for AstraZeneca COVID-19 Vaccine Booster
AstraZeneca reports that its COVID-19 vaccine (Vaxzevria), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody response to the Omicron variant.
Read More
Delta Variant May Evade Vaccine Immunity
Vaccines conferred protection from all COVID-19 variants but there was reduced antibody neutralization of both the Beta and Delta variants.
Read More
Merck VaxNeuvance Pneumococcal Vaccine Approved in EU
The European Commission approved Merck’s VaxNeuvance (Pneumococcal 15-valent Conjugate Vaccine) for prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.
Read More
Positive Data for Coadministered Flu and COVID Vaccines
Positive results from the first co-administration study of a SARS-CoV-2 vaccine candidate and an approved influenza vaccine have been published in The Lancet Respiratory Medicine.
Read More
Merck to License COVID-19 Antiviral to Drugmakers in Other Companies
Merck has entered into a voluntary licensing agreement to allow the production of its investigational COVID-19 antiviral molnupiravir by drugmakers in 105 low- and middle-income countries.
Read More
Novavax Pursuing UK Authorization for COVID-19 Vaccine
Novavax has completed its rolling regulatory submission for authorization of its NVX-CoV2373 COVID-19 vaccine candidate in the United Kingdom.
Read More
Positive Data for Valneva COVID-19 Vaccine
The French pharmaceutical company Valneva announced positive topline results from the Phase 3 trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Read More